Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in Scotland

Bennette C, Trinidad S, Fullerton S, Patrick D, Amendola L, Burke W, Hisama F, Jarvik G, Regier D, Veenstra D (2013) Return of Incidental Findings in Genomic Medicine: measuring what patients value – development of an instrument to measure preferences for information from next-generations testing (IMPRINT). Genet Med 15(11) https://doi.org/10.1038/gim.2013.63

Boycott K, Vanstone M, Bulman D, MacKenzie A (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nature 14. https://doi.org/10.1038/nrg3555

Braun V, Clarke V (2014) What can “thematic analysis” offer health and wellbeing researchers? Int J Qual Stud Health Well-Being 9:26152. https://doi.org/10.3402/qhw.v9.26152

Buchanan J, Wordsworth S, Schuh A (2016) Patients’ preferences for genomic diagnostic testing in chronic lymphocytic leukaemia: a discrete choice experiment. Patient 9:525–536

Buchanan J, Gavan S, Ryan M, Thompson A, Wordsworth S (2021) Moving exome and genome sequencing into clinical practice in England and Scotland: is the current health economics evidence base sufficient. Journal of Community Genetics: Special Issue on Resource Allocation in Genomic Medicine

Chassagne A, Pélissier A, Houdayer F, Cretin E, Gautier E, Salvi D, Kidri S, Godard A, Thauvin-Robinet C, Masurel A, Lehalle D (2019) Exome sequencing in clinical settings: preferences and experiences of parents of children with rare diseases (SEQUAPRE study). Eur J Hum Genet, p.1. https://doi.org/10.1038/s41431-018-0332-y

Chief Scientist Office (2019) Health Improvement, Protection and Services Research Committee 2019: Projects Funded in 2019. Should Scotland provide whole genomic sequencing for diagnosis of rare disorders: a health economic analysis. Available at: https://www.cso.scot.nhs.uk/outputs/cso-funded-research/hips2019/

Cleland J, Porteous T, Skatun D (2018) What can discrete choice experiments do for you? Med Educ 52(11):1113–1124. https://doi.org/10.1111/medu.13657

Drummond MF, Sculpher M, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press

Firth H, Wright C, for the DDD Study (2011) The Deciphering Developmental Disorders (DDD) study. Dev Med Child Neurol 53(8). https://doi.org/10.1111/j.1469-8749.2011.04032.x

Doble B, Schofield D, Evans CA, Groza T, Mattick JS, Field M, Roscioli T (2020) Impacts of genomics on the health and social costs of intellectual disability. J Med Genet. https://doi.org/10.1136/jmedgenet-2019-106445

Donaldson C (1990) Willingness to pay for publicly-provided goods: a possible measure of benefit? J Health Econ 9(1):103–118. https://doi.org/10.1016/0167-6296(90)90043-3

Genomics England (2018) About the rare disease programme. Accessed January 2019. Available at: https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/information-for-gmc-staff/rare-disease-documents/

Goranitis I, Best S, Christodoulou J, Stark, Z, Boughtwood T (2020) The personal utility and uptake of genomic sequencing in paediatric and adult conditions: eliciting societal preferences with three discrete choice experiments. Genet Med 22:1311–1319. https://doi.org/10.1038/s41436-020-0809-2

Hilbert J, Ashizawa T, Day J, Luebbe E, Martens W, McDermott M, Tawil R, Thornton C, Moxley R (2013) Diagnostic odyssey of patients with myotonic dystrophy. J Neurol 260(10):2497–2504. https://doi.org/10.1007/s00415-013-6993-0

Lejeune C, Amado I (2021) Valuing genetic and genomic testing in France: current challenges and latest evidence. J Community Genet. https://doi.org/10.1007/s12687-020-00503-2

Lewis C, Sanderson S, Hill M, Patch C, Searle B, Hunter A, Chitty L (2020) Parents’ motivations, concerns and understanding of genome sequencing: a qualitative interview study. Eur J Hum Genet 18:874–884. https://doi.org/10.1038/s41431-020-0575-2

Lewis MA, Stine A, Paquin RS, Mansfield C, Wood D, Rini C, Bailey DB Jr (2018) Parental preferences toward genomic sequencing for non-medically actionable conditions in children: a discrete-choice experiment. Genet Med 20(2):181. https://doi.org/10.1007/s12687-020-00503-210.1038/gim.2017.93

Mackley M, Blair E, Parker M, Taylor J, Watkins H, Ormondroyd E (2018) Views of rare disease participants in a UK whole-genome sequencing study towards secondary findings: a qualitative study. Eur J Hum Genet 26:652–659. https://doi.org/10.1038/s41431-018-0106-6

Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA (2016) What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med 18:1295–1302. https://doi.org/10.1038/gim.2016.6

Marshall DA, MacDonald K, Heidenreich S, Hartley T, Bernier F, Gillespie M, McInnes B, Innes A, Armour C, Boycott K (2019) The value of diagnostic testing for parents of children with rare genetic diseases. Genet Med 21:2798–2806. https://doi.org/10.1038/s41436-019-0583-1

McCarthy M, Lourenco R, McMillan L, Meshcheriakova E, Cao A, Gillam L (2020) Finding out what matters in decision-making related to genomics and personalised medicine in pediatric oncology: developing attributes to include in a discrete choice experiment. Patient 13(3):347–361. https://doi.org/10.1007/s40271-020-00411-0

National Services Scotland (2019) A guide to Scotland’s national specialist commissioner. Available at: https://www.nss.nhs.scot/media/1071/nsd-service-guide.pdf

NHS Scotland (2019) Genomics for rare disease in NHS Scotland. The Bridge to a Scottish Strategy for Genomics. Report 1 (June 2019) Available from: https://www.sglc.scot.nhs.uk/wp-content/uploads/2019/08/Genomics-Bridge-Report-1-June-2019-v1.0-1.pdf

Norbury G, Stenhouse S, Deller J, Curtis A, Cresswell L, The Association of Clinical Genetics Science (2016) Establishment of a unit to measure test activity to serve as a common currency in a genetics laboratory network. Available at: https://www.acgs.uk.com/quality/

Ontario Health (Quality) (2020) Genome-wide sequencing for unexplained developmental disabilities or multiple congenital anomalies: a health technology assessment. Ont Health Technol Assess Ser [Internet]. 2020 Mar;20(11):1–178. Available from: https://www.hqontario.ca/evidence-to-improvecare/health-technology-assessment/reviews-and-recommendations/genome-wide-sequencing-forunexplained-developmental-disabilities-and-multiple-congenital-anomalies

Payne K, Gavan SP, Wright SJ, Thompson AJ (2018) Cost-effectiveness analyses of genetic and genomic diagnostic tests. Nat Rev Genet 19(4):235–246. https://doi.org/10.1038/nrg.2017.108

Peyron C, Pélissier A, Béjean S (2018) Preference heterogeneity with respect to whole genome sequencing. A discrete choice experiment among parents of children with rare genetic diseases. Soc Sci Med 214:125–132. https://doi.org/10.1016/j.socscimed.2018.08.015

Pélissier A, Peyron C, Béjean S (2016) Next-generation sequencing in clinical practice: from the patients’ preferences to the informed consent process. Public Health 138. https://doi.org/10.1016/j.puhe.2016.03.011

Phillips K, Deverka P, Marshall D, Wordsworth S, Regier D, Christensen K, Buchanan J (2018) Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions. Value in Health. 21 (9). https://doi.org/10.1016/j.jval.2018.06.017

Plöthner M, Frank M, von d. S (2017) Cost analysis of whole genome sequencing in German clinical practice. European J Health Econ 18(5):623–633. https://doi.org/10.1007/s10198-016-0815-0

Pollard S, Weymann D, Dunne J, Mayanloo F, Buckell J, Buchanan J, Wordsworth S, Friedman JM, Stockler-Ipsiroglu S, Dragojlovic N, Elliott A, Harrison M, Lynd L, Regier D (2021) Toward the diagnosis of rare childhood genetic diseases: what do parents value most? Eur J Hum Genet. https://doi.org/10.1038/s41431-021-00882-1

Raftery J (2000) Costing in economic evaluation. The British Medical Journal. https://doi.org/10.1136/bmj.320.7249.1597

Reference Cost Collection: National Schedule of Reference Costs. (2017–18) NHS trusts and NHS foundation trusts. Available at: https://improvement.nhs.uk/resources/reference-costs/ Accessed 21 Feb 2019

Regier D, Friedman JM, Makela N, Ryan M, Marra C (2009) Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children. Clin Genet 75(6):514–521. https://doi.org/10.1111/j.1399-0004.2009.01193.x

Regier D, Peacock S, Pataky R, van der Hoek K, Jarvik G, Hoch J, Veenstra D (2015) Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. Can Med Assoc J 187(6):E190–E197. https://doi.org/10.1503/cmaj.140697

Regier DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S (2018) Valuation of health and nonhealth outcomes from next-generation sequencing: approaches, challenges, and solutions. Value in Health 21(9):1043–1047. https://doi.org/10.1016/j.jval.2018.06.010

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody W, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm H, ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30

Rigby D, Vass C, Payne K (2020) Opening the ‘black box’: an overview of methods to investigate the decision-making process in choice-based surveys. The Patient – Patient-Centered Outcomes Research, 13, pp 31–41. https://doi.org/10.1007/s40271-019-00385-8

Ryan M, Watson V, Entwistle V (2008) Rationalising the ‘irrational’: a think aloud study of discrete choice experiment responses. Health Economics 18 (3) https://doi.org/10.1002/hec.1369

Schwarze K, Buchanan J, Taylor JC, Wordsworth S (2018) Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med 20(10):1122–1130. https://doi.org/10.1038/gim.2017.247

Schofield D, Rynehart L, Shresther R, White S, Stark Z (2019) Long-term economic impacts of whole exome sequencing for suspected monogenic disorders. Twin Research and Human Genetics 21(5):404. https://doi.org/10.1038/s41436-019-0534-x

Scottish Government (2014) It’s not rare to have a rare disease – the implementation plan for rare diseases in Scotland. Available at: https://www.gov.scot/binaries/content/documents/govscot/publications/strategy-plan/2014/07/rare-rare-disease/documents/rare-rare-disease/rare-rare-disease/govscot%3Adocument/00455471.pdf

Scottish Genomes Partnership. (2020) Rare disease collaboration with the Genomics England 100,000 Genomes Project. Available at: https://www.scottishgenomespartnership.org/sgp-100-000-genomes-project

Scottish Health Technologies Group. (2017). Guidance documents for SHTG patient and public involvement. Available from: http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg

Scottish Medicines Consortium (2017) Guidance to manufacturers for completion of New Product Assessment Form (NPAF)

Scottish Science Advisory Council. (2019) Informing the future of genomic medicine in Scotland. Edinburgh: SSAC.

Smith HS, Swint JM, Lalani SR, Yamal JM, De Oliveira Otto MC, Castellanos S, Taylor A, Lee BH, Russell HV (2019) Clinical application of genome and exome sequencing as a diagnostic tool for pediatric patients: a scoping review of the literature. Genet Med 21(1): 3–16. https://doi.org/10.1038/s41436-018-0024-6

Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, Levy Y, Glazer D, Wilson J, Lawler M, Boughtwood T (2019) Integrating genomics into healthcare: a global responsibility. The American Journal of Human Genetics 104(1):13–20. https://doi.org/10.1016/j.ajhg.2018.11.014

Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care. 19 (6). https://doi.org/10.1093/intqhc/mzm042

Tsiplova K, Zur R, Marshall C, Stavropoulos D, Pereira S, Merico D, Young E, Sung W, Scherer S, Ungar W (2017) A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med 19. https://doi.org/10.1038/gim.2017.47

Van Nimwegen K, van Soest R, Veltman J, Nelen M, van der Wilt G, Vissers L, Grutters J (2016) Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing. Clinical Chemistry. 62 (11). https://doi.org/10.1373/clinchem.2016.258632

Weymann D, Dragojlovic N, Pollard S, Regier D (2019) Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges. Journal of Community Genetics: Special Issue on Resource Allocation in Genetic and Genomic Medicine. https://doi.org/10.1007/s12687-019-00428-5

Weymann D, Veenstra D, Jarvik G, Regier D (2018) Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment. Eur J Hum Genet. 26 (9). (2018). https://doi.org/10.1038/s41431-018-0161-z

Yuen T, Carter MT, Szatmari P, Ungar WJ (2018) Cost-effectiveness of genome and exome sequencing in children diagnosed with autism spectrum disorder. Appl Health Econ Health Policy 16(4):481–493. https://doi.org/10.1007/s40258-018-0390-x

Zhang W, Chen X, He G, Wang S, Lin S, Chen J (2019) Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterise resistance genes in clinical multi-drug resistance mycobacterium tuberculosis isolates from China. Front Microbiol 10:1741. https://doi.org/10.3389/fmicb.2019.01741